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BACKGROUND: Cancer-associated fibroblasts (CAFs)
were shown to be important for tumour progression in
head and neck squamous cell carcinomas (HNSCCs).
Their heterogeneity and lack of specific markers is
increasingly recognized. Integrin a11 was recently shown
to be expressed by CAFs and might serve as a specific
CAF marker.
AIM: To investigate integrin a11 expression and its
correlation with the expression of a well-known marker
of CAF, alpha smooth muscle actin (a-SMA), in HNSCC.
METHODS: Fresh frozen (FF) and formalin-fixed paraf-
fin-embedded (FFPE) samples from healthy volunteers
(n = 24), oral lichen planus (OLP) (n = 32) and HNSCC
(n = 106) were collected together with clinical data after
ethical approval. Immunohistochemistry to detect inte-
grin a11 and a-SMA was performed on FF and FFPE
samples. qPCR for integrin a11 (ITGA11) and a-SMA
(ACTA2) was performed on FF samples. Data were
analysed using chi-square test and Kaplan–Meier survival
analysis.
RESULTS: Significantly higher levels of integrin a11 and
a-SMA at both protein and mRNA levels were found in
HNSCC vs. normal controls and OLP. A strong correla-
tion was found between integrin a11 and a-SMA
expression, and double staining showed their colocaliza-
tion. Both integrin a11 and a-SMA were detected
surrounding metastatic islands. Expression of a-SMA at
tumour front but not tumour centre correlated with
patient survival.
CONCLUSION: Integrin a11 was overexpressed in
HNSCC stroma and colocalized with a-SMA. Expression
of a-SMA at tumour front but not tumour centre had
prognostic value for survival, pinpointing the importance
of assessing tumour front when evaluating stromal
molecules as prognostic biomarkers.
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Introduction
The underlying connective tissue stroma is essential for the
maintenance of epithelial tissues in normal conditions (1).
As the epithelium changes, the stroma predictably changes.
Fibroblasts are connective tissue cells that play a central role
in pathological events such as fibrosis and carcinogenesis
(2). Increasing evidence demonstrates that the progression
of carcinoma is not solely due to genetically altered tumour
cells, but also a result of the interactions between trans-
formed tumour cells and surrounding non-neoplastic cell
compartment (2). One example is the invasiveness of
transformed keratinocytes that can be triggered by pro-
invasive signals from the stromal fibroblasts, one of the
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major cell types found in the stroma of carcinomas (3).
Another study that indicated a major role for fibroblasts in
carcinoma cell invasion showed that carcinoma cells
invaded the underlying matrix by moving within tracks
already shaped by fibroblasts (4). Nevertheless, the some-
how established concept that stroma has a crucial role for
carcinoma progression is now being challenged by very
recent studies on pancreas adenocarcinoma (5, 6). Regard-
less of their role for carcinoma progression, fibroblasts in
the tumour stroma are most often activated. Several studies
have described the activation of carcinoma-associated
fibroblasts (CAFs) and their transdifferentiation towards a
myofibroblastic phenotype (expressing a-SMA) in carci-
noma arising in different locations, including head and neck
squamous cell carcinoma (HNSCC) (7).
The presence of myofibroblasts in the stroma of tongue
and oral cancer has been associated with poor prognosis by
several studies (8–11). Integrin-mediated interactions
between extracellular matrix and the cytoskeleton seem to
promote myofibroblast differentiation (12). Collagen-bind-
ing integrins a1b1 (13) and a2b1 (14) were the first shown
to influence myofibroblast differentiation under some con-
ditions in vitro. Another collagen receptor, a11b1, has been
also shown to regulate myofibroblast differentiation (15).
Integrin a11 is expressed in many tissues in the embryo but
disappears with maturation in adult tissues (16). However, it
has been proved that its expression is upregulated in
malignant conditions such as non-small-cell lung carci-
noma, where it has been suggested to be connected to cancer
cell growth (17, 18). We also showed previously overex-
pression of integrin a11 in CAFs isolated from oral
squamous cell carcinomas, but its expression in patient
samples with either oral or head and neck carcinomas was
not investigated at that time (19).
The aim of this study was to investigate the expression
pattern of integrin a11 in HNSCC and its correlation with
the well-known myofibroblast marker a-SMA.
We provide here data showing that integrin a11 is
overexpressed in stroma of primary HNSCC and that it
colocalizes with a-SMA. Expression of a-SMA at tumour
front but not tumour centre had prognostic value for patient
survival, indicating that tumour front is essential for
evaluating stromal molecules as prognostic biomarkers in
HNSCC.
Patients, materials and methods
Clinical cohort
The study has been ethically approved by the Committee for
Ethics in Health Research of West Norway (2010/481/REK
vest). Patients with oral dysplasia and HNSCC diagnosed
and treated at Haukeland University Hospital (HUS)
between 2001 and 2005 were included in the study to
allow a minimum of 10-year survival data (n = 162).
Inclusion criteria for selection were cases with (i) histolog-
ically confirmed diagnosis of oral dysplasia or HNSCC, (ii)
treatment with primary surgery only, (iii) presence of fresh
frozen (FF) and formalin-fixed, paraffin-embedded (FFPE)
material from the resection surgery (stored in the diagnosis
archive at Department of Pathology, HUS) and (iv) presence
of follow-up records (10-year survival data) in the electronic
journal system (DIPS). A cohort of 111 retrospective
archival biopsies fulfilling these criteria (106 with the
histological diagnostic of HNSCC – Table 1, and 5 of oral
dysplasia) was identified. Normal human oral mucosa
(NHOM) tissue samples from healthy volunteers undergo-
ing wisdom tooth removal (n = 24), and tissue biopsies
from patients with lichen planus (n = 32) were collected
after informed consent and used as controls. Lichen planus
was chosen as a disease model for chronic inflammation,
where fibroblasts are also known to be activated. All FF
samples were used for immunohistochemistry (IHC),
mRNA extraction and qPCR. FF tissues from cervical
lymph node metastases (n = 2), FFPE from oral dysplasia
(n = 5), recurrent HNSCC (n = 5), cervical lymph node
metastases (n = 12) and femur metastasis (n = 1) were also
included. Demographic, pathological and clinical features of
HNSCCs were collected from electronic patient journal
system at HUS (DIPS) following REMARK criteria (20)
(Table 1).
RNA extraction and qPCR
Archival frozen tissue stored at 80°C was cut (3 cryosec-
tions, 30 lm) and preserved in RNALater (Ambion,
Applied Biosystems, Warrington, UK). Samples were
digested with nuclease-free proteinase K at 60°C. RNA
was extracted using RNeasy kit (Qiagen, Valencia, CA,
USA), and total RNA was quantified and qualitatively
checked with NanoDrop 1000 Spectrophotometer (Wilm-
ington, DA, USA). RNA inclusion criteria for single-gene
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assays were >1.8 260/230 ratio and >1.8 260/280
ratio. Total RNA (200–300 ng) was converted to cDNA
(Transcriptor cDNA kit; Roche, Burgess Hill, UK). qRT-PCR
amplifications for ITGA11 and ACTA2 were performed on
LightCycler 480 qPCR system (Roche) using LightCycler
480 Probes Master (#04707494001; Roche). Comparative
2DDCt method was used to quantify relative mRNA
expression. GAPDH and ACTB were used as endogenous
controls.
Immunohistochemistry
Fresh frozen samples were sectioned at 3 microns thick-
ness and fixed in 50% ice-cold acetone (30 s) and then
100% ice-cold acetone (5 min). To block unspecific
binding, sections were incubated with 10% normal goat
serum (DAKO, Glostrup, Denmark) (30 min). Slides were
then treated with polyclonal antibody for integrin a11 1/
2000 (21) or monoclonal antibody for a-SMA 1/50
(Thermo Scientific, Waltham, MA, USA). Slides were
treated with secondary antibody Envision+ kit (DAKO)
(30 mi), and the bound reaction was visualized using 3, 30-
diaminobenzidine tetra hydrochloride (DAB, DAKO).
For negative controls, antibody diluent only was used.
Positive staining of blood vessels was used as internal
Figure 1 Expression of integrin a11 (A and B) and a-SMA (ACTA2) (C and D) is upregulated in HNSCC at mRNA level when compared to normal
human oral mucosa (NHOM) and oral lichen planus (OLP). The relative mRNA expression (y-axis) is plotted as individual data points in A and C and the
correlation curve between the level of expression and disease status (x-axis) is shown. The same data (relative mRNA expression on y-axis) is summarized for
each disease status (NHOM, OLP or HNSCC) and shown as box plots in B and D.
Table 2 Analysis of mRNA expression of integrin a11 (ITGA11) and
a-SMA (ACTA2) on frozen samples from NHOM (n = 24), OLP (n = 32)
and HNSCC (n = 102)
ITGA11 NHOM OLP HNSCC
Q75 5.5E-02 7.2E-02 1.5E-01
Max 3.8E-01 4.3E-01 9.2E-01
Min 4.7E-05 1.6E-08 1.0E-06
Q25 8.9E-03 7.9E-03 2.9E-02
Median 2.2E-02 4.1E-02 6.6E-02




Comments: Moderately upregulated in HNSCC only
ACTA2 NHOM OLP HNSCC
Q75 4.0E+00 8.9E+00 2.3E+01
Max 2.9E+01 3.7E+01 1.3E+02
Min 1.3E-01 3.5E-02 5.8E-06
Q25 9.4E-01 2.1E+00 3.4E+00
Median 1.7E+00 4.8E+00 8.2E+00




Comments: Moderately upregulated in OLP (highlighted in light grey) and
highly upregulated in HNSCC (highlighted in dark grey)
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positive control for each section. A competitive blocking
IHC using human integrin a11 peptide (NH2–)
CRREPGLDPTPKVLE (–COOH) (INNOVAGEN AB,
Lund, Sweden) was performed for validation of the
specificity of integrin a11 antibody. FFPE samples were
sectioned, deparaffinized in xylene and rehydrated in
decreasing alcohol gradient. Epitope retrieval was per-
formed by heating sections in citrate buffer pH 6.0 in a
microwave. The rest of the staining procedure was
performed following the same protocol as for FF samples.
Integrin a11 antibody could not be optimized for use on
FFPE samples. Double immunostaining was performed on
FF sections only and carried out using a double stain kit
(Envision G|2 double stain system, DAKO) following
manufacturer’s instructions as previously described (22).
IHC evaluation
Blinded for clinical information, IHC evaluation was carried
out at 2009 using Leica DMLB microscope (Leica
Microsystems, Heidelberg, Germany) by HP, SA and IC
after three sessions of calibration with DEC and KS.
Expression of integrin a11 and a-SMA was evaluated
semiquantitatively at three different areas at the central
region of the tumour (tumour propria) and at the invading
front tumour (IFT) area (available only on FFPE tissues and
defined as a 100-um broad tissue area around the outermost
invasive tumour islands). Immunoreactivity was scored
according to the proportion (density) of positively stained
stromal fibroblasts as either ‘poor’ (1–3 concentric layers of
spindle-shaped positively stained fibroblasts around tumour
islands) or ‘rich’ (more than three concentric layers of
spindle-shaped positively stained fibroblasts around tumour
with a crossing network pattern).
Data analysis
Statistical analysis was performed using SPSS version 20
(IBM, Armonk, NY, USA). Kaplan–Meier (KM) survival
analysis was performed with a log-rank (Mantel–Cox) test
for comparison between curves for overall survival (OS),
which was defined by death from any cause. Gene expression
was compared using Student’s t-test, nonlinear regression
analysis and box-whiskers plot for the determination of
significance, correlation and data distribution, respectively.
Results
Clinical and pathological characteristics of the study cohort
Demographic characteristics showed a homogenous cohort
with 98% of patients being Caucasian. Median age was
63 years (range 33–87) and 75% were males. The
specimens originated mainly from tongue, gingiva, larynx
and/or vocal cords, and pharynx, tonsils and/or uvula
(Table 1).
Integrin a11 was significantly upregulated in the stroma of
HNSCC compared with the submucosa of normal and
lichen planus tissues at both mRNA and protein levels
Quantitative PCR showed that mRNA for integrin a11
(ITGA11) was significantly expressed higher in HNSCC
than in NHOM (P = 0.004) and OLP (P = 0.021) patients
(Fig. 1A, Table 2). IHC staining of FF tissues for integrin
a11 protein was negative in both epithelial and stromal
compartments of NHOM (Fig. 2A) and OLP tissues
(Fig. 2B), while being positive in the stroma of 63.2% of
intraoral HNSCC and 66.7% of extraoral HNSCC samples.
When expressed, integrin a11 displayed a ‘rich’ pattern in
the majority of HNSCC (76.2% of intraoral HNSCC and
70% of extraoral HNSCC samples, Fig 2D) when compared
to 23.8% and 30% of intra- and extraoral HNSCC,
respectively, that expressed integrin a11 in a ‘poor’ pattern
(Fig. 2C). No predilection for a network or spindle pattern
of integrin a11 expression was found for intraoral or
extraoral cancers. Positively stained cells were also detected
surrounding the subcapsular lymph node metastases
(Fig. 2E). Expression of integrin a11 at the protein level
was found to be significantly upregulated in tumour stroma
of HNSCC when compared to NHOM (P < 0.001) and
OLP (P < 0.001).
Expression of integrin a11 strongly correlated with the
expression of a-SMA and the proteins were colocalized in
HNSCC patient tissues
Quantitative PCR showed that mRNA for a-SMA (ACTA2)
was significantly expressed higher in HNSCC than in
NHOM (P < 0.001) and OLP (P = 0.007) patients
(Fig. 1B, Table 2). Its mRNA expression was also found
to be upregulated in lichen planus when compared to normal
controls (P = 0.012, Table 2). Analysis of FF samples
showed that staining for a-SMA protein was negative in
NHOM (Fig. 2F) and OLP (Fig. 2G), with the exception of
pericytes around blood vessels, but positive in 55.3% of
intraoral HNSCC and 51.9% of extraoral HNSCC samples
(Fig. 2H,I). The presence of a-SMA at protein level (IHC)
was strongly correlated with the disease status (P = 0.000).
a-SMA displayed a ‘rich’ expression pattern (Fig. 2I) in
57.1% of intraoral HNSCC and 54.8% of extraoral HNSCC
samples cases and a ‘poor’ pattern (Fig. 2H) in 42.9% and
45.5%, respectively. A predilection (P = 0.020) for a ‘rich’
a-SMA expression pattern was found for intraoral vs.
extraoral cancers. There was a strong positive correlation
Figure 2 Expression of integrin a11 and a-SMA in FF (tumour centre) is upregulated in HNSCC at protein level when compared to normal mucosa and
lichen planus. IHC for integrin a11 is shown for normal (A), lichen planus (B), primary HNSCC (C and D) and regional lymph node metastasis of HNSCC
(E), and for a-SMA in normal oral mucosa (F), lichen planus (G), primary HNSCC (H and I) and regional lymph node metastasis of HNSCC (J) (2009
magnification). Immunoreactivity was scored according to the proportion (density) of the positively stained stromal fibroblasts as either ‘poor’ (1–3
concentric layers of spindle-shaped positively stained fibroblasts around tumour islands), as exemplified in C and H or ‘rich’ (more than three concentric
layers of spindle-shaped positively stained fibroblasts around tumour with a crossing network pattern), as exemplified in D and I. Double immunostaining for
integrin a11 (brown) and a-SMA (red) was also performed on FF samples (K–O, 4009 magnification). Double-stained positive cells were observed around
acini of salivary gland tissue and this served as internal positive control (K). L shows a tumour stroma with predominance of elongated cells positive for
integrin a11 (brown colour) while M shows a tumour stroma with predominance of elongated cells positive for a-SMA (red colour). Note the blood vessels
expressing predominantly a-SMA (red colour), as observed in the single staining as well. N and O show a tumour stroma with elongated cells equally
positive for integrin a11 (brown colour) and a-SMA (red colour).
J Oral Pathol Med








J Oral Pathol Med
Integrin a11 in head and neck cancer
Parajuli et al.
271
between the expression of a-SMA and integrin a11 when
analysed in FF tissues (r = 0.735, P = 0.000). Positively
stained cells were also detected surrounding the subcapsular
lymph node metastases (Fig. 2J). Double immunostaining
for integrin a11 and a-SMA revealed colocalization of the
two proteins in most of the cases (Fig. 2N,O).
Expression of integrin a11 and/or a-SMA at tumour centre
(FF samples) did not correlate with survival of patients with
HNSCC
Survival analysis showed no correlations between the IHC
score in FF samples and OS neither for integrin a11 nor for
a-SMA (Fig. 3A,B). Analysis of the FF samples stained
with haematoxylin and eosin revealed that none of the
samples contained the invasive tumour front (ITF). There-
fore, selection of FFPE samples of HNSCC containing the
ITF was further carried out and IHC for both integrin a11
and a-SMA was performed on those samples.
Expression of a-SMA in a ‘rich’ pattern at tumour front
correlated with poor survival of patients with HNSCC
Only a-SMA antibody could be optimized for staining on
FFPE tissues, and therefore, only a-SMA could be quanti-
fied at the ITF. The staining was negative in NHOM
(Fig. 4A), and oral dysplasia (Fig. 4B) with the exception
of blood vessels, but positive in 94.23% of the tumour
stroma of primary HNSCC tissues (Fig. 4C,D), all local
recidives, and around all metastases investigated, both in the
loco-regional lymph nodes and at distance (Fig. 4E,F). At
the tumour centre, 60.8% of HNSCC showed a-SMA-
positive fibroblasts in a ‘poor’ pattern and 39.2% in a ‘rich’
pattern, while at the ITF 70% of HNSCC showed a-SMA
fibroblasts in a ‘poor’ pattern and 30% in a ‘rich’ pattern.
KM survival analysis showed that the presence of a-SMA
fibroblasts in a ‘rich’ pattern was predictive of a poor
survival only when present at ITF (P = 0.021) (Fig. 3C),
but not at tumour centre (P = 0.06) (Fig. 3B). As it was
previously reported a correlation between a-SMA staining
and survival for oral and tongue tumours (8–11), but not for
other sites of mouth (23) and head and neck, we analysed
separately HNSCC at other sites and found that there was a
correlation between the pattern of a-SMA staining at tumour
front and survival for other sites of HNSCC than tongue
(Fig. 4D).
Discussion
In order to investigate the potential of integrin a11 as a new
prognostic marker, we have assessed it together with a
previously established marker of poor prognosis in oral and
Figure 3 Survival analysis (Kaplan–Meier curves) showing no correlation between the expression of integrin a11 (A) or a-SMA (B) and overall survival
when quantified at tumour centre (FF samples). Correlation between the ‘rich’ expression pattern of a-SMA at ITF (FFPE samples) and overall survival was
found for both: all sites including tongue (C) and other sites than tongue (D).
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tongue carcinoma, a-SMA. Our results are in line with
previous studies on a-SMA expression (8–10, 24), showing
a correlation of ‘rich’ expression of a-SMA with poor
survival in HNSCC. Nevertheless, this observation was
found when a-SMA was evaluated at ITF, and not at the
tumour centre in either FF or FFPE samples. This demon-
strates the importance of analysing representative tissue
material for assessing the prognostic value of a putative
biomarker. This corroborates well with previous studies that
showed differences in the expression and prognostic value
of various other potential biomarkers such as proliferation
marker Ki67, p63, E-cadherin, RPS6 or when evaluated at
ITF and tumour centre (tumour propria) (25–28). The
importance of the ITF for the progression and prognostica-
tion in oral/head and neck cancer has been actually
pinpointed already for two decades ago (29). It was defined
as the most progressed, three to six tumour cell layers or
detached tumour cell groups at the advancing edge of an
oral SCC (29). Most of studies involving ITF did not define
it precisely, and thus, differences in the outcomes of the
studies could be due to differences in the area defined as
ITF. In this study, we have defined ITF as the 100-lm broad
tissue area around the outermost invasive tumour islands,
and we have scored it in three different, randomly chosen
areas in order to accommodate for the intratumour hetero-
geneity (30). We have observed heterogeneity both at the
ITF area and in tumour propria and have scored tumours as
‘homogeneous’ or ‘heterogeneous’ according to their sim-
ilar/differential expression of integrin a11 and a-SMA at the
three different areas. We could not detect any correlations
between heterogeneity of tumours and clinicopathological
parameters neither at ITF nor at tumour centre for any of the
proteins investigated.
Intertumour heterogeneity is also highlighted by this
study that found 38.2% of cases not expressing a11 or a-
SMA, while the rest of the cases showed variable degree of
protein expression. Nevertheless, the ‘rich’ pattern of a-
SMA expression was found to be more a characteristic of
intraoral than of extraoral HNSCC and a correlation
between the expression of a-SMA in a ‘rich’ pattern at
the ITF and shorter survival time was found. Of interest,
when analysing separately the tongue SCC and other sites, a
correlation between the expression of a-SMA in a ‘rich’
pattern at ITF and shorter survival for other head and neck
sites than tongue (which comprised 75% of all cases of this




Figure 4 Expression of a-SMA is upregulated in HNSCC at protein level when compared to normal mucosa. IHC for a-SMA in normal human oral
mucosa (NHOM) (A), dysplastic (B), HNSCC tumour front (C) and tumour centre (D), lymph node metastasis (E) and femur metastasis (F). All metastasis
were found to express a-SMA in a ‘rich’ pattern.
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finding as such correlations were previously reported mainly
for tongue SCC or for cohorts including a significant
number of tongue SCC.
The use of both FF and FFPE samples makes this study
unique, as previous studies investigated either FF or FFPE
samples only. We found a strong correlation between the
expression of a-SMA in FF and the expression of a-SMA in
FFPE samples, although more HNSCC (94.23%) expressed
a-SMA when stained on FFPE tissues than when stained on
FF tissues (61.8%). This difference was due to a more
abundant expression of a-SMA in the stroma at ITF than
centrally in the tumour. Of note, both integrin a11 and a-
SMA were found to be expressed in spindle-shaped cells
surrounding the tumour islands in all the metastatic lymph
nodes investigated, suggesting that tumour cells are sur-
rounded by an activated stroma also at the metastatic sites.
Investigation of lymph nodes without metastasis showed a
rim of a-SMA-positive cells surrounding the nonmetastatic
lymph nodes, but not within the nodes. However, this could
not answer the question of whether the activated stroma
surrounding the metastasis is carried over from the primary
tumour or it arises ‘de novo’ at the site of the metastatic
implantation.
Analysis of both a11 and a-SMA in FF samples did not
show any correlation with patient survival, although a
significant correlation between the disease status (SCC) and
their expression was found. However, as FF samples did not
contain the ITF, these results are not surprising, because in
FFPE samples we could only demonstrate a correlation with
the patient survival when a-SMA was evaluated at ITF and
not centrally in the tumour. Taking into consideration that
the staining for integrin a11 could not be optimized for
FFPE material, the expression of integrin a11 could only be
evaluated at the tumour centre, and here its pattern of
expression was found not to correlate with patient survival.
However, there was a strong positive correlation between
integrin a11 and a-SMA staining in HNSCC, demonstrating
that the expression of these two proteins follows the same
pattern in the tumour stroma of this tumour type. It should
be also noted that both integrin a11 and a-SMA were
exclusively expressed by activated fibroblasts of tumour
stroma and were not part of the activated fibroblast
phenotype in the chronic inflammatory disease lichen
planus. In addition, as integrin a11 was expressed by a
higher percentage of HNSCC than a-SMA, it seems to be
more frequently than a-SMA a characteristic of the
activated phenotype of CAFs.
In conclusion, the main finding of this study is that
integrin a11 was found to be overexpressed in the stroma of
most HNSCC and it colocalized with a-SMA. Expression of
a-SMA at invasive tumour front but not tumour centre had
prognostic value for patient survival, pinpointing the
importance of assessing the invasive tumour front when
evaluating the potential of various stromal molecules as
prognostic biomarkers.
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